KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Invested Capital: 2009-2025

Historic Invested Capital for Novavax (NVAX) over the last 15 years, with Sep 2025 value amounting to -$156.7 million.

  • Novavax's Invested Capital rose 70.24% to -$156.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$156.7 million, marking a year-over-year increase of 70.24%. This contributed to the annual value of -$563.1 million for FY2024, which is 21.46% up from last year.
  • As of Q3 2025, Novavax's Invested Capital stood at -$156.7 million, which was down 516.40% from $37.6 million recorded in Q2 2025.
  • Novavax's 5-year Invested Capital high stood at $1.0 billion for Q1 2021, and its period low was -$895.6 million during Q1 2023.
  • For the 3-year period, Novavax's Invested Capital averaged around -$511.7 million, with its median value being -$563.1 million (2024).
  • In the last 5 years, Novavax's Invested Capital soared by 245.19% in 2021 and then crashed by 1,470.98% in 2023.
  • Quarterly analysis of 5 years shows Novavax's Invested Capital stood at -$351.7 million in 2021, then tumbled by 80.30% to -$634.1 million in 2022, then decreased by 13.07% to -$716.9 million in 2023, then grew by 21.46% to -$563.1 million in 2024, then surged by 70.24% to -$156.7 million in 2025.
  • Its Invested Capital stands at -$156.7 million for Q3 2025, versus $37.6 million for Q2 2025 and -$75.6 million for Q1 2025.